- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04478513
A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers
A Phase I, Open-label, Non-randomised Study to Assess the Effect of Fluvoxamine (CYP1A2 Inhibitor) and Smoking (CYP1A2 Inducer) on the Pharmacokinetics of a Single Oral Dosing of AZD4635 in Healthy Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will comprise:
- A screening period of up to 28 days;
- Two treatment periods lasting a total of 17 days from admission to the Clinical Unit (Day -1) to discharge (Day 16). During each treatment period subjects will receive a single dose of AZD4635 under fasting conditions. Period 1 is designed to evaluate the pharmacokinetics (PK) of AZD4635 in healthy smokers and non-smokers. Period 2 is designed to evaluate the effect of fluvoxamine on the PK of AZD4635 in healthy smokers and non-smokers.
- A follow-up call will take place between 6 to 9 days after the last dose of fluvoxamine, to ensure the well-being of the subjects. Completion of the last follow-up call or unscheduled follow-up visit will be considered the end of the study.
Each subject will be involved in the study for a maximum of 53 days.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Harrow, United Kingdom, HA1 3UJ
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Provision of signed and dated, written informed consent prior to any study specific procedures.
- Healthy male and female subjects of non-childbearing potential subjects aged 18 - 55 years (inclusive at screening) with suitable veins for cannulation or repeated venipuncture.
- Have a body mass index (BMI) between 18.5 and 32.0 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg, inclusive.
- Willingness and ability to comply with study and follow-up procedures.
- Subjects who are recruited as non-smokers should have no history of smoking cigarettes for >6 months and test negative for urine cotinine levels at screening and admission.
- Subjects who are recruited as smokers must have a history of smoking >10 cigarettes/day for >6 months and have urine cotinine levels over 500 ng/ml at screening and admission.
Exclusion Criteria:
- History of any clinically significant disease or disorder which, in the opinion of the principal investigator (PI), may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study.
- History or presence of gastrointestinal (GI), hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
- History of cardiac disease; concurrent electroconvulsive therapy, diabetes mellitus, epilepsy, bleeding disorders (especially GI bleeding), mania and susceptibility to angle-closure glaucoma.
- Presence of refractory nausea and vomiting or chronic GI diseases.
- Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of investigational medicinal product (IMP).
- Any clinically significant abnormalities in clinical chemistry, haematology, or urinalysis results, as judged by the PI (based on laboratory parameters).
- Any clinically significant abnormal findings in vital signs at screening as judged by the PI.
- Systolic blood pressure (BP) >140 and/or diastolic BP > 90 mmHg, or history of hypertension at screening.
- Any confirmed clinically significant abnormalities on 12-lead ECG at screening, as judged by the PI.
- Haemoglobin A1c (HbA1c) >5.7% at the screening visit.
- Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibodies.
- Known or suspected history of drug abuse, within the past 2 years, as judged by the PI.
- Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study.
- Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening.
- History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the PI.
- Positive screen for drugs of abuse at screening or admission to the study centre.
- Use of herbal preparations/medications within 14 days prior to the administration of the first dose of AZD4635.
- Subject who has had prescription or non-prescription drugs or other products known to be sensitive to Breast cancer resistance protein.
- Use of any prescribed or non prescribed medication including antacids, analgesics, herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP.
- Subjects who have involvement with AstraZeneca or Parexel or are study site employee or their close relatives.
- Subjects who have previously been enrolled in this study or have previously received AZD4635.
- Judgment by the PI that the subject should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Smokers
Pre-specified group of participants.
|
During each treatment period subjects will receive a single dose of AZD4635 under fasting conditions.
Daily oral single doses of fluvoxamine are planned to be administered to healthy volunteers in Treatment Period 2.
|
EXPERIMENTAL: Non-smokers
Pre-specified group of participants.
|
During each treatment period subjects will receive a single dose of AZD4635 under fasting conditions.
Daily oral single doses of fluvoxamine are planned to be administered to healthy volunteers in Treatment Period 2.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the plasma concentration-time curve from time zero to infinity (AUC)
Time Frame: Days 1-6 and Days 11-16
|
To assess the effect of fluvoxamine and smoking on the PK of AZD4635 following single oral dosing in healthy volunteers
|
Days 1-6 and Days 11-16
|
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC0-t)
Time Frame: Days 1-6 and Days 11-16
|
To assess the effect of fluvoxamine and smoking on the PK of AZD4635 following single oral dosing in healthy volunteers
|
Days 1-6 and Days 11-16
|
Maximum observed plasma concentration (Cmax)
Time Frame: Days 1-6 and Days 11-16
|
To assess the effect of fluvoxamine and smoking on the PK of AZD4635 following single oral dosing in healthy volunteers
|
Days 1-6 and Days 11-16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects with adverse events, serious adverse events and deaths
Time Frame: From Screening upto Day 24
|
To assess adverse events as a variable of safety and tolerability of AZD4635 when dosed with and without fluvoxamine in smokers and non-smokers
|
From Screening upto Day 24
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Pablo Forte Soto, Dr., Parexel Early Phase Clinical Unit London
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Anti-Anxiety Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Fluvoxamine
Other Study ID Numbers
- D8730C00007
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the
Disclosure Statements at:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteer/DDI Study
-
Atea Pharmaceuticals, Inc.Not yet recruiting
-
Comanche BiopharmaRecruiting
-
NewAmsterdam PharmaCompletedHealthy Volunteer StudyUnited States
-
BioAge Labs, Inc.CompletedHealthy Volunteer StudyNew Zealand
-
Wake Forest University Health SciencesTerminated
-
Atea Pharmaceuticals, Inc.Hoffmann-La RocheCompleted
-
Denovo Biopharma LLCCompleted
-
Atea Pharmaceuticals, Inc.Hoffmann-La RocheCompleted
-
Atea Pharmaceuticals, Inc.Hoffmann-La RocheCompleted
-
Orion Corporation, Orion PharmaCompletedHealthy Volunteer StudyFinland
Clinical Trials on AZD4635
-
AstraZenecaQuotient SciencesCompleted
-
AstraZenecaCompletedAdvanced Solid MalignanciesJapan
-
AstraZenecaParexelCompletedProgressive Metastatic Castrate-Resistant Prostate CancerUnited States, Spain, Belgium, France, Korea, Republic of
-
AstraZenecaCompletedProstate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)United States
-
MedImmune LLCActive, not recruitingCarcinoma, Non-Small-Cell LungUnited States, Korea, Republic of, Taiwan
-
AstraZenecaCompletedAdvanced Solid Malignancies | Non-Small Cell Lung Cancer (NSCLC) | Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC) | Colorectal Carcinoma (CRC)United States